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Abstract Bone remodeling is a tightly regulated process
securing repair of microdamage (targeted remodeling) and
replacement of old bone with new bone through sequential
osteoclastic resorption and osteoblastic bone formation. The
rate of remodeling is regulated by a wide variety of
calcitropic hormones (PTH, thyroid hormone, sex steroids
etc.). In recent years we have come to appreciate that bone
remodeling proceeds in a specialized vascular structure,—
the Bone Remodeling Compartment (BRC). The outer
lining of this compartment is made up of flattened cells,
displaying all the characteristics of lining cells in bone
including expression of OPG and RANKL. Reduced bone
turnover leads to a decrease in the number of BRCs, while
increased turnover causes an increase in the number of
BRCs. The secretion of regulatory factors inside a confined
space separated from the bone marrow would facilitate
local regulation of the remodeling process without interfer-
ence from growth factors secreted by blood cells in the
marrow space. The BRC also creates an environment where
cells inside the structure are exposed to denuded bone,
which may enable direct cellular interactions with integrins
and other matrix factors known to regulate osteoclast/
osteoblast activity. However, the denuded bone surface
inside the BRC also constitutes an ideal environment for
the seeding of bone metastases, known to have high affinity
for bone matrix. Circulating osteoclast- and osteoblast
precursor cells have been demonstrated in peripheral blood.
The dominant pathway regulating osteoclast recruitment is
the RANKL/OPG system, while many different factors
(RUNX, Osterix) are involved in osteoblast differentiation.
Both pathways are modulated by calcitropic hormones.
Keywords Osteoblasts.Osteoclasts.Lining cells.Growth
factors.Cytokines.Bone remodeling.Osteoporosis.Bone
remodeling compartment
1 Introduction
Bone histomorphometry has given us great insights into
bone physiology and bone remodeling in particular.
Histomorphometric indices obtained using tetracycline
double labeling techniques are unique, because they
contrary to DXA and bone markers reflect cellular activity
of osteoclasts and osteoblasts using the incorporation of a
time marker, namely spaced administration of an agent
(tetracycline) reflecting ongoing active bone formation. The
study of bone remodeling originated with the classical
works of Harold Frost 40 years ago [1] and our ever
expanding understanding of this process is the basis for the
development of highly effective treatments for osteoporo-
sis, that we have seen over the last 20 years.
2 The bone remodeling cycle
Although macroscopically the skeleton seems to be a static
organ, it is an extremely dynamic tissue at the microscopic
level. The ability of bone to sustain the tremendous loads
placed on it in everyday life depends on, constant repair of
mechanical microdamage that develops both in cancellous
bone—the “spongy” bonepresent inthe vertebrae,pelvis,and
ends (metaphyses) of long bones—and in cortical bone—the
compact bone present in the shafts (diaphyses) of the long
bones and surrounding cancellous bone as a thin layer in the
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concerted action of resorptive and formative cell populations
inordertoreplaceoldbonewithnewboneandthussecurethe
integrity of the skeleton. This sequence has to be tightly
regulated by both local and systemic factors, because
significant deviations from a neutral balance between resorp-
tion and formation would mean severe accelerated bone loss
or bone gains with possible disastrous consequences in terms
of increased fracture risk or compression syndromes.
Bone remodeling takes place in what Frost termed the
Basic Multicellular Unit (BMU), which comprises the
osteoclasts, osteoblasts, and osteocytes within the bone-
remodeling cavity (Fig. 1). In cancellous bone remodeling
occurs on the surface of trabeculae and lasts about 200 days
in normal bone. The remodeling cycle can be as short as
100 days in thyrotoxicosis and primary hyperparathyroid-
ism and exceed 1,000 days in low turnover states like
Myxedema and after bisphosphonate treatment [2]. Remod-
eling is initiated by osteoclastic resorption, which erodes a
resorption lacuna, the depth of which varies between 60 in
young individuals and 40 μm in older individuals. The
resorption period has a median duration of 30–40 days and
is followed by bone formation over a period of 150 days
(Fig. 1)[ 3, 4]. In normal bone the result of the remodeling
cycle is complete refilling of the resorption lacuna with new
bone. In disease states like osteoporosis, the main defect is
that the osteoblast is unable to refill the resorption lacuna
leading to a net loss of bone with each remodeling event
[5]. In cortical bone remodeling proceeds in tunnels with
osteoclasts forming “cutting cones” removing damaged
bone followed by refilling by osteoblasts in the “closing
cone” occurring behind the osteoclasts [6]. In normal bone
the duration of the remodeling cycle in cortical is shorter
than in cancellous bone with a median of 120 days [6]. The
total surface of cancellous bone is completely remodeled
over a period of 2 years.
Contrary to remodeling sites in cancellous bone,
w h i c ha r ec l o s et or e dm a r r o w ,k n o w nt oc o n t a i n
osteoprogenitor cells [7], remodeling sites in cortical bone
are distant from red marrow. Therefore, it was assumed
that the mechanisms of bone remodeling were different in
cancellous versus cortical bone, i.e. that the cells needed
for bone remodeling in cancellous bone traveled directly
from the red marrow to bone surfaces in cancellous bone,
while cells reached cortical remodeling sites bone via the
vasculature [8].
2.1 Osteoblast differentiation
Osteoblasts are mesenchymal cells derived from mesoder-
mal and neural crest progenitor cells and their formation
entails differentiation from progenitors into proliferating
preosteoblasts, bone matrix-producing osteoblasts, and
eventually into osteocytes or a bone-lining cells. The
earliest osteoblastic marker, Runt-related transcription
factor 2 (Runx2) is necessary for progenitor cell differen-
tiation along the osteoblast lineage [9]. During this
sequence of cellular proliferation Runx2 regulates expres-
sion of genes encoding osteocalcin, VEGF, RANKL,
sclerostin, and dentin matrix protein 1 [DMP1] [10].
Osterix is another transcription factor essential for osteo-
blast differentiation [11]. A large number of paracrine,
autocrine, and endocrine factors affect osteoblast develop-
ment and maturation like: bone morphogenetic proteins
(BMPs), growth factors like FGF and IGF, angiogenic
factors like endothelin-1, hormones like PTH and prosta-
glandin agonists, all modulate osteoblast differentiation
[12]. The action of PTH and BMPs is closely associated
with activation of Wnt signalling pathways [13].
The fully differentiated osteoblast is characterized by
coexpression of alkaline phosphatase and type I collagen,
both important for synthesis of bone matrix and
subsequent mineralization thereof [14]. Mature osteo-
blasts also produce regulators of matrix mineralization
like osteocalcin, osteopontin and ostenectin, RANKL
which is necessary for osteoclast differentiation as well
as the receptor for PTH (PTHR1). At the end of their
lifespan osteoblasts transform into either osteocytes which
become embedded in the mineralized matrix or lining
cells, which cover all surfaces of bone. Specific molecules
expressed by osteocytes include DMP1, FGF 23 and
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Fig. 1 Schematic representation of Bone Multicellular Units (BMUs)
in cancellous and cortical bone. Broken lines denote the outer limit of
Bone Remodeling Compartment associated with the resorptive and
formative sites of the BMU. The mean thickness of the structure in
cancellous bone is 50 μm and 80 μm in cortical bone equivalent to a
mean Haversian system diameter of 160 μm. The Blood supply for the
BRCs is provided by capillaries either coming from the marrow space
as is the case for cancellous BMUs or from the central vessel of
Haversian systems in cortical bone. The duration of the remodeling
sequence is somewhat longer in cancellous than in cortical bone. The
position of marrow cappillaries is hypothetical, as the exact
distribution is poorly elucidated
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metabolism [15].
2.1.1 Wnts and osteoblast differentiation
Wnts are secreted glycoproteins crucial for the development
and renewal of many tissues, including bone. Wnt
signalling dominate osteoblast differentiation pathways
and act via binding to a receptor complex consisting of
LDL receptor-related protein 5 (LRP5) orLRP6 and one of
ten Frizzled molecules [13]. The so called canonical Wnt
signaling pathway is active in all cells of the osteoblastic
lineage, and involves the stabilization of β-catenin and
regulation of multiple transcription factors [16]. Wnt/β-
catenin signaling is also important for mechanotransduc-
tion, fracture healing and osteoclast maturation [17–19].
The activation of canonical Wnt-signaling promotes
osteoblast differentiation from mesenchymal progenitors at
the expense of adipogenesis, which leads to improved bone
strength, while suppression causes bone loss [20]. Canon-
ical Wnt signaling in osteoblast differentiation is modulated
by Runx2 and osterix [21].
Wnt signaling is a prime target for bone active drugs and
the approaches include inhibition of Wnt antagonist like
Dkk1, sclerostin, and Sfrp1 with neutralizing antibodies
and inhibition of glycogen synthase kinase 3 β (GSK3 β),
which promotes phosphorylation and degradation of β-
catenin. One of the most promising approaches so far has
been inhibition of the osteocyte protein sclerostin, which
exerts tonic inhibition of osteoblast activity [22]. Sclerostin
is the product of the SOST gene, which is mutated and
downregulated in patients with sclerosteosis and van
Buchem disease and sclerosteosis [23], which are diseases
characterized by high bone density. Expression levels of
sclerostinare repressedinresponsetomechanicalloading and
intermittent PTH treatment [24]. Preliminary studies with a
humanized monoclonal antibody against sclerostin have
shown bone anabolism in animals as well as humans [25].
2.2 Osteoclast differentiation
The dominating pathway regulating osteoclast differentia-
tion is the RANKL/RANK/OPG pathway. This pathway is
based on osteoblasts promoting osteoclast differentiation
through membrane presentation of RANKL and binding of
this factor to the membrane receptor RANK on mononu-
clear osteoclast precursors. Osteoclast differentiation is also
modulated by M-CSF [26]. The promotion of osteoclast
differentiation by RANKL is inhibited by the decoy
receptor osteoprotegerin (OPG), which is also produced
by osteoblasts [26] (74). Estrogens increase OPG and
decrease RANKL expression in osteblasts, thus favoring
bone formation. Postmenopausal bone loss is linked to
reduced estrogen levels favoring increased resorption. In
many instances [26]. PTH given as daily injections favors
bone anabolism, reduces RANKL and increases OPG
levels. In cases with chronic elevation of circulating PTH
levels as seen in primary hyperparathyroidism the opposite
pattern is seen with elevated RANKL and reduced OPG
levels. A humanized monoclonal antibody against RANKL
has been shown to elicit even more pronounced reduction
in osteoclast numbers [27] than bisphosphonates and has
demonstrated excellent reduction of fracture risk in post-
menopausal osteoporosis [28].
2.3 Coupling between resorption and formation
During normal bone remodeling, the amount of resorbed
bone is completely replaced in location and amount by new
bone. This is secured through tight coupling of bone
resorption to bone formation. The mechanisms underlying
the coupling process still remains largely elusive, although
the last 15 years has increased our knowledge significantly.
The dominating hypothesis years ago was that liberation
of growth factors like IGF 1 and 2 and cytokines embedded
in bone matrix during bone resorption secured the balance
between resorption and formation during bone remodeling
[29]. Later work showing that osteoblastic bone formation
proceeds unperturbed despite lack of bone resorption in the
presence of defective osteoclasts lacking for example
chloride channels or important factors for ruffled border
formation in osteoclasts like c-Src [30] has supplemented
this hypothesis. The important role that osteoclasts play in
the regulation of bone formation is also corroborated by
studies on mice lacking c-fos or M-CSF, which display
absence of osteoclasts and defective bone formation [31].
Other system involved in coupling of bone resorption to
bone formation are the transmembrane proteins, ephrinB2,
which are expressed on osteoblasts and EPH receptor B4
(EphB4), which are expressed on osteoclasts [32]. Also the
osteoclastic factor sphingosine 1-phosphate (S1P) [33]
seems to play a significant role. The interaction of Ephrin
and EPH by cell to cell contact promotes osteoblast
differentiation and represses osteoclast differentiation.
Secretion of S1P by osteoclast seems to recruit osteoblast
progenitor cells to sites of bone resorption and stimulate
differentiation of these progenitor cells by stimulating
EphB4 signaling, This causes a shut down of bone
resorption and initiate the formative phase of bone
remodeling in the so called transition phase.
3 Targeted and non-targeted remodeling
Through its constant removal and renewal of damaged
bone, bone remodeling secures skeletal integrity throughout
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targeted and non-targeted (stochastic) remodeling. Non-
targeted remodeling denotes regulation remodeling by
hormones like PTH, thyroxine, growth hormone and
estrogen, but also antiresorptive drugs like bisphospho-
nates may affect non-targeted remodeling. It seems that
the main pathway is via modulation of osteoclasts, which
then via the coupling between resorption and formation
subsequently affects osteoblast activity. Targeted remod-
eling secures removal of damaged bone through targeted
resorption. Osteocytes are the most abundant cells in
bone, and their death by microdamage has been suggested to
bethemajoreventleadingintheinitiationofosteoclasticbone
resorption. In normal bone [34]. Resorption lacunae are 3
times more frequent inassociationwithmicrocracks, indicating
that remodeling is associated with repair of such microdamage
[35]. Damaged osteocytes promote differentiation of osteo-
clast precursors driven by secretion of M-CSF and RANKL
[36]. In cortical bone there is evidence to suggest, that
microdamage not only activates new BMUs, but may also
may direct the movement of existing BMUs as they tunnel
through the cortex. It also seems that the degree of damage to
the osteocyte network determines osteocyte metabolic
responses to loading and influences targeted remodeling [37].
Analysis of the relationship of between mean microcrack
length and BMU resorption space density in cortical bone
indicates that BMUs have an effective area about 40 times
greater than their actual cross-section, which suggests that
osteoclasts in the cutting cone of cortical BMUs are able to
sense and steer toward microdamage [38]. The relation
between microdamage and initiation of bone remodeling is
further corroborated by the fact that osteoclastic resorption
is augmented in old bone [39].
4 The bone remodeling compartment
The work by Hauge et al. [40] demonstrated that the cells in
the BMU, even in cancellous bone, were not directly
contiguous to the bone marrow, but rather they were
covered by a “canopy” of cells forming the outer lining of
a specialized vascular structure with the denuded bone
surface as the other delineation. The cells of this canopy
display all classicial markers of the osteoblastic phenotype
(Table 1), and are therefore most probably bone-lining cells,
which seem to be connected to bone-lining cells on the
quiescent bone surface. The structure has been demonstrat-
ed in cortical as well as cortical bone (Fig. 2). In turn, these
bone-lining cells on the quiescent bone surface are in
communication with osteocytes embedded within the bone
matrix. Penetrating the canopy of bone-lining cells, and
presumably serving as a conduit for the cells needed in the
BMU, are capillaries.
Table 1 Osteoblastic and endothelial markers detected on cells lining
the Bone remodeling Compartment (BRC) vs. vascular endothelial
cells as assessed by immuno- and enzyme histochemical staining
Antigen BRC Vascular endothelium
VEGF – +
Von Willebrand Factor – +
CD 34 – +
Alkaline Phosphatase* + –
Osteocalcin + –
Osteonectin + –
IGF 1,2 + –
TGF β 1,2,3 + –
bFGF + –
OPG + –
RANKL + –
CV EG
EG
OC
OC
Ob
Fig. 2 Different representations of BRC structures in cortical (upper
panel) and trabecular bone (lower panel). In cortical bone the BRC
(outer demarcation by the broken line) is filled with erythrocyte ghosts
(EG) and is located at the closing cone of the Haversian system
situated over osteoblasts (OB). A few osteoclasts (OC) are also seen.
CV denotes the central vessel of the Haversian system. In trabecular
bone (lower panel) the outer lining of the BRC is clearly discernible,
demarcating a vascular structure on top of osteoblasts (OB). Picture in
upper panel courtesy of Pierre Delmas, Lyon, France
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and bone and angiogenic factors like VEGF and endothelin
regulate osteoclast and osteoblast activity [41]. In addition
blood vessels serve as a way of transporting circulating
osteoblast [42] and osteoclast precursors [43]t os i t e s
undergoing active remodeling. The involvement of vascular
cells during the initiation of bone resorption is still
unresolved. Is the very first step adhesion of a blood vessel
to bone lining cells at a site where targeted repair is
needed? Conceivably, osteocyte apoptosis and possible
release of osteotropic growth factors and cytokines could
be attractants for blood vessels, which would then subse-
quently initiate the formation of a resorptive BRC. But, as
outlined above, the framework for signaling within the
osteocyte-lining cell-BRC network could also be a way by
which remodeling events on bony surfaces are triggered
from damage accumulation or changes in mechanical strain
within bone.
There is increasing evidence for a common lineage and
close interaction between vascular endothelial cells and
bone cells. Endothelial cells drive differentiation of marrow
stromal cell towards the osteoblastic phenotype [44]
Endothelin and VEGF are also involved in signaling
between vasculature and bone [45], and VEGF as well as
other angiogenic factors are expressed during intramem-
branous osteogenesis. Osteoblastic cells, as well as osteo-
clasts, possess receptors for VEGF and also produce VEGF
[46]. Expression of VEGF is closely associated with the
early phases of bone modeling and remodeling events [47]
and it induces osteoblast chemotaxis and differentiation
[48] and differentiation.
Cells may enter the remodeling space either via
diapedesis through the lining cell dome covering the BRC
or via the circulation. It is still debatable whether all cells
involved in remodeling arrive via the circulation, but while
circulating osteoclast precursors were demonstrated more
than a decade ago, there is now increasing evidence that
osteoblast lineage cells are also present in the circulation
strengthening the involvement of circulating precursor cells
in the process [42, 49, 50].
While the systemic hormonal regulation of the remodel-
ing process has to occur via factors arriving at individual
remodeling sites via the bloodstream, the way by which
local regulatory factors exert their action on individual cell
populations involved is still obscure. Over the last decades,
however, we have increased our knowledge about the
different growth factors and cytokines involved in local
regulation of bone remodeling tremendously (Fig. 3). Apart
from growth factors and cytokines, simple molecules like
nitrogen oxide (NO), as well as hypoxia and acidosis have
been shown to exert pronounced effects on bone remodel-
ing balance and activity. NO exerts biphasic effects on
osteoclast activity with low concentrations potentiating and
high concentrations inhibiting bone resorption [51]. Simi-
larly, osteoblastic growth and differentiation are inhibited
by high concentrations of NO, while lower concentrations
may play a role in regulating normal osteoblast growth and
in mediating the effects of estrogens on bone formation,
mechanotransduction and bone anabolic responses [51].
The dominating isoform of nitrogen oxide synthase (eNOS)
is expressed in osteocytes and lining cells, but not in
cuboidal osteoblasts [52]. Acidosis and hypoxia generally
increase bone resorption [53–56] and inhibit bone forma-
tion [57]. As hypoxia may cause acidosis through increased
anaerobic metabolism, the two factors may act synergisti-
cally at the tissue level [56]. Hypoxia and acidosis also
affect secretion of pro-angiogenic factors like VEGF as
outlined below.
5 Key functions of the bone remodeling compartment
1. The BRC provides a closed microenvironment permit-
ting tight regulation of bone remodeling. Current
concepts regarding local regulation of bone remodeling
generally assumes that the local growth factors,
cytokines and even NO come either from cells in the
marrow space or vascular cells having free access to the
remodeling site without barriers, or are produced by
osteoclasts and osteoblasts at the remodeling site. The
BRC concept implies that the all factors liberated from
the cells or vessels in the marrow space exert their
regulatory role either through diffusion through the
outer layer of the BRC, transport via the bloodstream to
the interior of the BRC or indirectly via modulation of
cell activity in the outer wall of the BRC. The presence
of a specific compartment in which remodeling can
proceed without interference from local factors liberat-
ed in the marrow space seems to be logical. If the
access to the marrow space was open, the very high
levels of growth factors in the marrow microenviron-
ment might offset eventual localized regulatory effects
by local growth factors, crucial to osteoclast and
osteoblast differentiation and the remodeling process.
2. The BRC is the structure translating microdamage into
targeted remodeling by which mechanosensory signals
from the osteocyte network are translated into changes
in osteoclast and osteoblast activity on trabecular
surfaces. Lining cells are connected to the osteocyte
network via gap junctions between lining cells on
quiescent surfaces and osteocyte cannaliculi [58]
(Fig. 4). Signals from lining cells indicating damage
or stress could be transmitted to the outer lining cell
layer of the BRC and trigger osteoclast recruitment. By
analogy with remodeling in cortical bone, which is
clearly associated with growth of a blood vessel into
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capillary into the BRC provides the vascular supply for
the cells in the BMU of cancellous bone and might also
provide the necessary osteoclasts and, subsequently, the
osteoblasts that are needed for bone remodeling in both
cancellous and cortical bone The BRC would also be a
site where hormonal modulation (e.g. ERT) of the
mechanosensory input could take place [59].
3. The BRC is the most probable structure at which
coupling between osteoclasts and osteoblasts occurs.
The RANKL/OPG pathway involves presentation of
osteoblastic, membrane bound RANKL to the RANK
receptor on osteoclast precursors by cell to cell contact.
Due to the timing and sequence of bone resorption and
bone formation, however, resorption and formation are
generally separated in time and space, which makes the
needed cell to cell contact between osteoclast precur-
sors and active osteoblasts highly unlikely on a broader
basis, and even if soluble RANKL played a major role
it had no RANKL on precursor cells within the BRC to
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Fig. 3 Depiction of some of the main local regulatory factors
operating at remodeling sites with osteoclasts (OC) and osteoblasts
(OB). Interleukins (IL), tumor necrosis factors (TNF), transforming
growth factors (TGF), colony stimulating factors (CSF), Insulin like
growth factors (IGF), fibroblast growth factors (FGF), platelet derived
growth factors (PDGF), bone morphogenetic proteins (BMP)) are
formed by both monocytic cells in the marrow space or circulation, as
well as bone cells in the BMU. NFκB- or RANK- ligand (RANKL)
and osteoprotegerin (OPG) are formed specifically by osteoblasts.
Factors from the marrow space as well as factors liberated by
endothelial cells (vascular endothelial growth factor (VEGF), endo-
thelin, nitrogen oxide (NO)) may diffuse to receptors on osteoclasts or
osteoblasts. The cellular responses in the BMU are then further
modulated by systemic hormones in the circulation (estrogen (E2),
parathyroid hormone (PTH), active vitamin D (1,25D), thyroid
hormone (T3)). Left lower insert depicts in detail osteoblast-
osteoclast interactions inside the BRC and right lower insert depict
an alternativ, still hypohetical, version of that interaction based on
lining cells acting as the osteoblastic component in thata interaction
OB
OC
MARROW CAPILLARY
OSTEOCYTES
Fig. 4 Connections between the osteocyte network, lining cells and the
BRC. All cells in this network are connected with gap junctions, which
m a yp r o v i d eap a t h w a y( block arrows), by which signals generated deep
within bone may reach the surface and elicit remodeling events by
osteoclasts (OC) and osteoblasts (OB) in response to mechanical
stimuli. The response may be modulated by factors liberated from the
vascular endothelium or marrow capillaries/sinusoids and paracrine
factors (broken arrow) liberated from lining cells may also play a role
224 Rev Endocr Metab Disord (2010) 11:219–227bind to. A more likely cell, which could present RANKL
to RANK on osteoclast precursors, would be the lining
cell. As demonstrated in animals [60] and in humans
[61], lining cells exhibit positive immunoreactivity for
OPG and RANKL, and might therefore be responsible
for the cell to cell contact with osteoclast precursors.
4. The BRC also obviates the need for a “postal code”
system ensuring that resorptive and formative cells
adhere to areas on the bone surface, where they are
needed. Bone surfaces are generally covered by lining
cells, which would prevent direct contact between bone
cells and integrins or other adhesion molecules known
to modulate cell activity. The BRC would be the only
place where these cells (circulating osteoclasts as well
as circulating osteoblast precursors) would be exposed
to these matrix constituents, because the formation of
the BRC involves detachment of lining cells from the
bone surface.
5. The BRC may play a crucial role in the spread of bone
metastases. It is well established that apart from
entering bone via local ingrowth, tumor cells reach
bony surfaces via the circulation. The growth of
metastatic cells in bone is enhanced by the so called
“vicious cycle”, where PTHrp produced by tumor cells
(e.g. breast cancer cells) induces increased local bone
resorption and subsequent liberation of TGFβ from the
bone matrix [62]. The local effects of TGFβ in the
bone microenvironment are two-fold: 1) it enhances the
growth of bone metastases and 2) increases PTHrp
formation from tumor cells further [62], thus maintain-
ing the vicious cycle. As shown above, one of the key
components of the vicious cycle, TGFβ, is produced by
the cells lining the BRC. Other key promoters of bone
metastases like IL-1 and IL-6 are also produced by the
lining cell layer covering BRCs. It is therefore probable
that the microenvironment in the BRC is highly
conducive to metastatic seeding and the formation of
the vicious cycle, further enabling growth of the bone
metastasis. Moreover, the existence of a closed com-
partment would make vicious cycle formation easier
due to absence of interference with cytokine and
growth factors from the marrow space. Several large
scale studies have established that bisphosphonates
reduce the number of skeletal events in breast cancer,
prostate cancer and myelomatosis, and iv bisphospho-
nates are now used routinely in advanced cancer [63].
There is still debate as to how much of the beneficial
effects of bisphosphonates in advanced cancer are due
to inhibition of angiogenesis or to other, direct anti-
tumor effects. Bisphosphonate, however, could exert
their inhibitory effects on bone metastases simply by
reducing the number of BRCs and thereby the surface
of denuded bone available for metastatic seeding.
6 Conclusion
Bone remodeling involves tight coupling and regulation of
osteoclasts andosteoblasts andismodulatedbya widevariety
of hormones and osteocyte products secreted in response to
mechanical stimulation and microdamage. Bone remodeling
proceeds in a specialized vascular entity the “Bone Remodel-
ing Compartment” (BRC), which provides the structural basis
for coupling and regulation of cellular activity. Increased
knowledge about the interplay between different factors and
cells surrounding the BRC will most likely result in even
better treatment options for skeletal disease.
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